

ISPOR SOUTH AFRICA CHAPTER ANNUAL CONGRESS 2017

16 - 17 September 2017 (Short Courses) & 18 - 19 September 2017 (Conference)

<u>Theme:</u> Partnering for better patient outcomes

Protea Hotel Marriott Balalaika, Maude Street, Sandton

	Saturday, 16 September 2017 Pre-Conference Short Course	
Time	Description	
13:00 - 17:00	Short Course 1 - Systematic reviews in comparative effectiveness research	
Presenter: Ilse Truter	A systematic review, also known as a structured literature review, summarises the results of available healthcare studies and provides a high level of evidence on the effectiveness of healthcare interventions. It differs from a meta-analysis, which also adds a statistical synthesis of findings across multiple studies. Comparative effectiveness research is a rigorous evaluation of the impact of different options that are available for treating a given medical condition for a particular set of patients. Its purpose is to assist consumers, clinicians, purchasers, and policy makers in making informed decisions that will improve health care at both individual and population levels. This course will cover systematic reviews in comparative effectiveness research, by focusing on five main areas: 1) evidence-based medicine (EBM) and the different types of literature reviews (the typology of reviews); 2) linking comparative effectiveness research and systematic reviews; 3) basic steps in performing a systematic review; 4) reporting of results; and 5) appraisal and use of systematic reviews in comparative effectiveness research. Interactive exercises will be an integral part of the course.	
	Sunday, 17 September 2017 Pre-Conference Short Courses	
Time	Description	
08:00 - 12:00	Short Course 2 - Meta-analysis in comparative effectiveness research	
Presenter: Laura Sawyer	 Meta-analysis can be defined as the statistical analysis of data from multiple studies for the purpose of synthesizing and summarising results, as well as for quantitatively evaluating sources of heterogeneity and bias. This course 1) outlines the rationale for meta-analysis; 2) describes statistical methods of combining data; and 3) introduces methods for indirect comparisons. The material draws on practical examples from the published literature relevant to pharmacoeconomic and outcomes research. This course is designed for those with little experience with meta-analysis and includes interactive exercises. Participants who wish to gain hands-on experience must bring their personal laptops with Review Manager 5 installed. 	
12:00 - 13:00	Lunch	
13:00 - 17:00	Short Course 3 - Introduction to pharmacoeconomic modelling	
Presenters: Tienie Stander Laura Sawyer	The basis of pharmacoeconomic modelling is decision analysis. This course will take an introductory look at the principles and practice of decision analysis. Participants will be taught the appropriateness of decision analysis in different settings, and how to construct simple decision trees and how to conduct simple sensitivity analysis. Simple examples will be used to illustrate these. Participants will also be introduced throughout the course, the recommendations of the joint SMDM/ISPOR modelling methods Good research practices recommendations.	

ISPOR South Africa Ltd (Association Incorporated under Section 21) Lynda Woods (President), Shelley McGee (Ex-officio President), Carolle Kinyua (Treasurer), Tienie Stander (President elect) Jacques Snyman, Johanita Burger, Harshal Thaker, Ilse Truter, Laura Sawyer, Tiffany Naidoo, Shaun Nomame



ISPOR South Africa Chapter Annual Conference Monday, 18 September 2017		
09:00	Welcome address - Lynda Woods (ISPOR South Africa Chapter President)	
05100		
09:10	Session 1: Lynda Woods Role of pharmacoeconomics and outcome research in clinical policy and benefit design: paving the way for a unified approach to HTA in South Africa - A legal and policy landscape analysis of HTA in South Africa: Tommy Wilkinson (PRICELESS) - Discovery Health Perspective: Dr Noluthando Nematswerani - MMI Perspective: Prof Manie De Klerk - University of Witwatersrand Perspective: Dr Jacqui Miot	
10:30	Tea Break	
11:00	 Session 2: Harshal Thaker From Data, to Decisions, to Savings: Tools for Navigating a Resource Constrained Healthcare Sector The value of PBM in a resource constrained environment: Hein Botha (MediKredit) The Use of AI and Decision support systems to improve patient outcomes which result in cost saving in Asthma: Thys Kruger (MSO) ICON / ISIMO Case Studies: Prof Jacques Snyman 	
12:15	Poster Presentations	
12:30	Lunch Break & Poster author discussion	
13:30	 Session 3: Carolle Kinyua Pharmaceutical Pricing policy in South Africa: past, present and future- is it time for reform? Medicine Pricing and Equity: Dr John Bartlett (Independent) Differential pricing in resource-constrained environments: Prof Jacques Snyman Value-based price efficiency modelling for South Africa, outcomes-based price and access models based on international principles/successes: Andy Gray (University of KZN) Topic TBC: Dr Tienie Stander (TCD Outcomes Research) 	
15:00	Tea Break	
15:15	Session 4: Laura Sawyer Careers in HEOR and Market Access: Hear from established professionals in the HEOR field about how to advance and develop your career path. Panel consisting of leading Academics, Market Access Professionals, HEOR Professionals in pharma and consulting, Government and Medical Aid, HERO and Actuaries. - TCD Outcome Research: Kudakwashe Bopoto - Novo Nordisk: Tom Molokwane - HE ² RO: Jacqui Miot - PRICELESS: Tommy Wilkinson	
16:00	AGM	



	Tuesday, 19 September 2017		
Time	Description		
09:00	Session 5: Shaun Nomame		
05.00	 Real World Evidence and the value it brings to Pharmacoeconomics and Outcomes Research Innovative use of data for value-based healthcare – International perspectives on real world evidence: Neil Soderlund and Joshila Shiba (Quantium Health Outcomes) Value based care and outcomes research in cancer: Dr Ernst Marais and Murray Izzett, (ISIMO) The value of real life data: Johann van Zyl (Clinical Governance Services) 		
10:30	Tea Break		
11:00	 Session 6: Tiffany Naidoo With the introduction of medical device regulations to the South African healthcare environment, medical device and diagnostic suppliers need to optimize regulatory and health economic processes. Health technology assessments: optimizing the data for an effective HTA outcome: Mark Brand (BRANDTECH) The difference between pharma and medical devices, why the parameters for evaluation are not the same: Riaan Meyer (Medtronic) Device regulations are now a reality: What does this mean to you? Madeleine Pearce (Phillips) Registries in the South African context - Learnings and Successes: Johan Serfontein (Cataract Registry) and Elsa van Duuren (SARAA Registry) 		
12:30	Lunch break		
13:30	Session 7: Shelley McGee Pharmacoeconomic modelling: How, who, why and with what? Who is doing what? Where is HTA being taught? How is it being applied? - Pharmacoeconomics as part of a market access and reimbursement strategy: Dr Tienie Stander (TCD Outcomes) - Economic modelling: Not a one-person job: Laura Sawyer (Symmetron) - Modelling contextual heterogeneity and its implications on decision-making: Dr Nicola Foster (UCT) - Actuarial modelling: Cristoff Raath (Insight)		
14:45	Session 8: Ilse Truter and Johanita Burger Research in Pharmacoeconomics and Outcomes Research		
15:00	Tea Break		
15:30	Session 9: Shelley McGee Discussion: Health Market Inquiry – The Proposed Outcome Body		
16:30	Consensus Session: Lynda Woods Takeaways and steps forward for HTA in South Africa		
17:00	Conference Closure		